Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
CRISPR Therapeutics AG
CRSP
Healthcare
Biotechnology
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this...
technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CRSP)
New Post
View:
Posts & Comments
Threaded Posts
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 3:54pm
CRISPR Therapeutics AG (NASDAQ:CRSP): A Pioneering Gene Edit
https://beyondspx.com/2024/07/31/crispr-therapeutics-ag-nasdaqcrsp-a-pioneering-gene-editing-company-poised-for-continued-growth/
(2)
•••
CreatingApe
X
Comment by
CreatingApe
on May 08, 2024 7:01pm
RE:regrets
Lol if you think it's a 1000 dollar stock it's definitely not too late. 52.22 at close today...
(274)
•••
whytestocks
X
Post by
whytestocks
on Feb 19, 2024 2:00am
If You Invested $10,000 in CRISPR Therapeutics in 2019, This
NEWS: $CRSP If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today2024-02-19 01:45:00 ET Companies in the biotech industry are often capable of delivering
...more
(104)
•••
foofadooo
X
Comment by
foofadooo
on Aug 25, 2022 8:19am
RE: Switzerland-based biotechnology leader
Eventually, it will be like owning a solid ETF. I view it similar to an ARKK or TSLA....it just requires some long term paitience! foof
(2)
•••
jw1trader
X
Post by
jw1trader
on Aug 24, 2022 12:51pm
Switzerland-based biotechnology leader
portfolio of therapies across a range of disease areas, including treatments for blood disorders, specialized cancers and other rare conditions. With strategic partnerships that include major players
...more
(4)
•••
Lisaslab
X
Post by
Lisaslab
on Aug 24, 2022 12:44pm
$4 billion CRISPR is a Switzerland-based biotechnology
biotechnology leader known for its cutting-edge platform to support gene editing and related development of genomic DNA medicines. It has a portfolio of therapies across a range of disease areas
...more
(104)
•••
foofadooo
X
Comment by
foofadooo
on Aug 19, 2021 7:25am
RE:regrets
IMHO.....it's not to late there will br many growth stocks springboard off CRSPR....CRBU... is a good example... foof
(1)
•••
phred7
X
Post by
phred7
on Dec 10, 2020 12:56am
regrets
I have been following this and 2 other CRISPR stocks for over 4 years... wow did I make a mistake. I did not buy. This is a health care bite me stock. I wish I had the 20/20 when the
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Rig Count Soars as Utilization Surpasses Industry Averages
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth